What is he best known for?
The fields of study he is best known for:
- Enzyme
- Biochemistry
- Amino acid
Kevin J. Barnham focuses on Biochemistry, Alzheimer's disease, Amyloid, Peptide and Cell biology.
His Biochemistry study combines topics in areas such as P3 peptide, Amyloid precursor protein and Neurodegeneration.
The PBT2 research Kevin J. Barnham does as part of his general Alzheimer's disease study is frequently linked to other disciplines of science, such as Genetically modified mouse, therefore creating a link between diverse domains of science.
His Amyloid study integrates concerns from other disciplines, such as Amyloid beta, Alpha-synuclein and In vivo.
His Amyloid beta research incorporates themes from Molecule and Stereochemistry.
His research integrates issues of Neurotoxicity, Histidine, Protein structure, Lipid bilayer and Membrane lipids in his study of Peptide.
His most cited work include:
- Neurodegenerative diseases and oxidative stress. (2450 citations)
- Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice (1215 citations)
- Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ (537 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Biochemistry, Peptide, Disease, Alzheimer's disease and Amyloid.
His studies deal with areas such as Neurotoxicity and P3 peptide, Amyloid precursor protein as well as Biochemistry.
His research investigates the connection between Peptide and topics such as Reactive oxygen species that intersect with problems in Oxidative stress.
His study focuses on the intersection of Disease and fields such as Neuroscience with connections in the field of Parkinson's disease and Neurodegeneration.
Kevin J. Barnham works mostly in the field of Alzheimer's disease, limiting it down to concerns involving In vitro and, occasionally, In vivo.
His research investigates the connection with Amyloid and areas like Alpha-synuclein which intersect with concerns in Substantia nigra and Fibril.
He most often published in these fields:
- Biochemistry (48.97%)
- Peptide (29.64%)
- Disease (23.45%)
What were the highlights of his more recent work (between 2013-2021)?
- Biochemistry (48.97%)
- Disease (23.45%)
- Neurodegeneration (14.69%)
In recent papers he was focusing on the following fields of study:
Kevin J. Barnham mainly focuses on Biochemistry, Disease, Neurodegeneration, Amyloid and Alzheimer's disease.
His work on Protein structure as part of general Biochemistry study is frequently linked to Gene isoform, therefore connecting diverse disciplines of science.
His Disease research includes elements of Neuroscience, Pediatrics and Cell biology.
His research in Neurodegeneration intersects with topics in Alpha-synuclein, Mechanism of action, Substantia nigra, Neuroprotection and PBT2.
He has researched Amyloid in several fields, including P3 peptide, Nuclear magnetic resonance spectroscopy, Stereochemistry, Beta and Peptide.
His biological study spans a wide range of topics, including Antibody, Immunology, Amyloid beta and Homeostasis.
Between 2013 and 2021, his most popular works were:
- Biological metals and metal-targeting compounds in major neurodegenerative diseases. (254 citations)
- Biological metals and metal-targeting compounds in major neurodegenerative diseases. (254 citations)
- Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis (105 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Amino acid
- Biochemistry
His main research concerns Biochemistry, Neurodegeneration, Fibril, Alzheimer's disease and Pharmacology.
Particularly relevant to Reactive oxygen species is his body of work in Biochemistry.
His work investigates the relationship between Fibril and topics such as Conformational isomerism that intersect with problems in Intrinsically disordered proteins, Copper, Protein folding and Peptide.
Kevin J. Barnham usually deals with Alzheimer's disease and limits it to topics linked to Homeostasis and Cellular compartment, Endogeny, Long-term potentiation, Amyloid precursor protein and Amyotrophic lateral sclerosis.
His Pharmacology research integrates issues from Substantia nigra, Lipid peroxidation and MPTP.
His work focuses on many connections between Amyloid and other disciplines, such as Clioquinol, that overlap with his field of interest in PBT2.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
